

1 **Sero-prevalence of anti-SARS-CoV-2 antibodies in Chattogram Metropolitan Area,**
2 **Bangladesh**

3 Jahan Ara¹, Md. Sirazul Islam^{2,3}, Md. Tarek Ul Quader⁴, Anan Das¹, F. M. Yasir Hasib^{2,5},
4 Mohammad Saiful Islam⁶, Tazrina Rahman⁷, Seemanta Das¹, M.A. Hassan Chowdhury⁸, Goutam
5 Buddha Das^{3,9}, and Sharmin Chowdhury^{1,2,3}.

6 ¹One Health Institute, Chattogram Veterinary and Animal Sciences University, Khulshi-4225,
7 Chattogram, Bangladesh;

8 ²Department of Pathology and Parasitology, Faculty of Veterinary Medicine, Chattogram
9 Veterinary and Animal Sciences University, Khulshi-4225, Chattogram, Bangladesh;

10 ³COVID-19 Detection Laboratory, Chattogram Veterinary and Animal Sciences University,
11 Khulshi-4225, Chattogram, Bangladesh;

12 ⁴Department of Anesthesiology and ICU, Chittagong Medical College Hospital, Chattogram,
13 Bangladesh;

14 ⁵Department of Infectious Diseases and Public Health, City University of Hong Kong, Hong Kong
15 SAR;

16 ⁶Department of Emergency and Accident, Imperial Hospital Limited, Chattogram, Bangladesh;

17 ⁷Department of Microbiology and Virology, Chittagong Medical College, Chattogram,
18 Bangladesh;

19 ⁸Department of Medicine, Chittagong Medical College, Chattogram, Bangladesh;

20 ⁹Department of Animal Science and Nutrition, Chattogram Veterinary and Animal Sciences
21 University, Khulshi-4225, Chattogram, Bangladesh.

22

23 *** Corresponding author:**

24 **Sharmin Chowdhury, PhD**

25 Director, One Health Institute, Chattogram Veterinary and Animal Sciences University, Khulshi,
26 Chattogram-4225.

27 E-mail: sharminchowdhury@cvasu.ac.bd

28

29 **Abstract**

30 **Background:** Seroprevalence studies of coronavirus disease 2019 (COVID-19) assess the degree
31 of undetected transmission in the community. Different groups, such as healthcare workers
32 (HCWs), garment workers, and others, are deemed vulnerable due to their workplace hazards and
33 immense responsibility.

34 **Purpose:** The present study was conducted to estimate the seroprevalence of anti-SARS-CoV-2
35 antibody (IgG) and its association with different explanatory variables. Further, the antibody was
36 quantified to assess the increasing or decreasing trend over different intervention periods and
37 according to other factors.

38 **Methodology:** This cross-sectional study observed health workers - doctor, nurse, hospital staff,
39 etc. in and outpatients (non-COVID-19) and garments workers of Chattogram metropolitan area
40 (CMA, N=748) from randomly selected six government and private hospitals and two garment
41 factories. Study subjects were included upon written consent, fulfilling specific inclusion criteria.
42 Venous blood was collected following standard aseptic methods. Qualitative and quantitative
43 ELISA was used to identify and quantify antibodies (IgG) in serum samples. Descriptive,
44 univariable, and multivariable statistical analysis was performed.

45 **Results:** Overall seroprevalence was estimated as 66.99% (95% CI: 63.40%-70.40%).
46 Seroprevalence among HCWs, in and outpatients, and garments workers were 68.99 % (95% CI:

47 63.8%-73.7%), 81.37 % (95% CI: 74.7%-86.7%), and 50.56 % (95% CI: 43.5%-57.5%),
48 respectively. Seroprevalence was 44.47 % (95% CI: 38.6%-50.4%) in the non-vaccinated
49 population while it was significantly ($p < 0.001$) higher in the population receiving the first dose
50 (61.66 %, 95% CI: 54.8%-68.0%) and both (first and second) doses of vaccine (100%, 95% CI:
51 98.4%-100%). The mean titer of the antibody was estimated as 255.46 DU/ml and 159.08 DU/ml
52 in the population with both doses and one dose of vaccine, respectively, compared to 53.71 DU/ml
53 of the unvaccinated population. A decreasing trend in the titer of antibodies with increasing time
54 after vaccination was observed.

55 **Conclusions:** Seroprevalence and mean antibody titer varied according to different factors in this
56 study. The second dose of vaccine significantly increased the seroprevalence and titer, which
57 decreased to a certain level over time. Although antibody was produced following natural
58 infection, the mean titer was relatively low compared to antibody after vaccination. This study
59 emphasizes the role of the vaccine in antibody production. Based on the findings, interventions
60 like continuing extensive mass vaccination of the leftover unvaccinated population and bringing
61 the mass population with a second dose under a third dose campaign might be planned.

62
63 **Keywords:** Seroprevalence, anti-SARS-CoV-2 antibody, antibody titer, IgG

64 65 **Introduction**

66 Chattogram, the port city of Bangladesh, is classified as a high-risk zone for SARS-CoV-2 contact
67 transmission and is one of the most crowded economic and trading centers [1]. On April 3, 2020,
68 Chattogram city witnessed its first Coronavirus Disease 2019 (COVID-19) positive case [2],
69 followed by the first death on 9 April [3]. The disease can manifest itself in various ways, from

70 asymptomatic and minor upper respiratory symptoms to severe pneumonia and acute respiratory
71 distress syndrome [4]. While nucleic acid amplification, such as polymerase chain reaction (PCR),
72 is the gold standard for diagnosing acute SARS-CoV-2 infection and is widely recommended, the
73 antibody-based approach improves diagnosis accuracy by capturing asymptomatic testing and
74 recovered infections [5].

75 During an infectious disease outbreak, seroprevalence investigations are crucial in revealing
76 undetected infection in the population and preventing post-pandemic reappearance [6].
77 Determining the actual burden of infection is also vital for epidemic forecasting and response
78 planning. Seroprevalence studies are potent in identifying the number of undiagnosed missing
79 cases with mild or no symptoms or who cannot undergo testing that may contribute significantly
80 to the transmission [7-11]. Further, seroprevalence studies estimate the susceptible population in a
81 community. A current investigation discovered that up to 23% of the patients diagnosed with
82 COVID-19 from December 2020 to February 2021 in Bangladesh were asymptomatic [12]. Thus,
83 antibody testing could be crucial to determine the actual SARS-CoV-2 exposure rates since PCR
84 only identifies the viral nucleic acid in individuals with existing symptoms [13].

85 According to numerous research, seropositivity fluctuates considerably depending on parameters
86 such as location and time [7, 14]. Antibody titers reach their peak one month after the onset of
87 symptoms, and their levels are directly proportional to the severity of the illness [15]. Titers
88 continue to fall after that, with IgM and IgA titers falling fast and IgG titers falling more slowly
89 [16]. However, a greater understanding of antibody responses to SARS-CoV-2 after natural
90 infection might aid in the development of more successful vaccination strategies in the future.
91 Bangladesh started administering COVID-19 vaccinations on January 27, 2021, and mass
92 immunization commenced on February 7, 2021 [17, 18]. As of December 21, 2021, 50.27% of the

93 target population had received the first dose, and 34.60% received the second dose [19].
94 Bangladesh has already started administering third doses to senior persons aged 60 and up, people
95 with comorbidities, and frontline workers. [20]. According to a web-based anonymous cross-
96 sectional survey conducted among the general Bangladeshi population between January 30 and
97 February 6, 2022, 61.16% of respondents were inclined to accept/take the COVID-19 vaccine [21].
98 However, vaccination coverage and seroprevalence among the general public must be investigated
99 nationwide to know the herd immunity.

100 In the COVID-19 pandemic, HCWs are facing immense challenges worldwide. Occupational
101 exposures among HCWs have been documented in numerous nations as worrying [22]. Likewise,
102 COVID-19 has had a significant impact on the healthcare system of Bangladesh. According to the
103 latest data from the Bangladesh Medical Association, between March 8, 2020, and November 11,
104 2021, 9455 HCWs, including physicians, nurses, and other staff, were infected with COVID-19,
105 as well as 188 doctors died as a result [23]. Front liners directly involved in diagnosing, treating,
106 and caring for COVID-19 patients are at risk of physical and psychological distress [24-29].
107 Similarly, workers in the garment industry confront different problems in the workplace all around
108 the world. According to the Bangladesh Garment Manufacturers and Exporters Association
109 (BGMEA), 4500 garment companies employ over 4.5 million people or nearly 2.5 percent of the
110 country's entire population [30]. The bulk of the industries operate with limited space, making it
111 challenging to enforce physical distancing norms [31]. SARS-CoV-2 transmission might be
112 exacerbated by crowded workplaces, transportation, and lack of physical distancing [32]. Hence,
113 it is necessary to put in place measures including risk management in the workplace, vulnerable
114 employee care, the development of an occupational surveillance system, and vaccination policy

115 administration to address the COVID-19 issues [33, 34]. Thus, knowing the true seroprevalence
116 both in the risk groups and community might assist in planning interventions efficiently.

117 In this study, we reported population-based SARS-CoV-2 seropositivity among HCWs, indoor and
118 outdoor patients of various government and private hospitals, and garment workers of CMA, as
119 determined by enzyme-linked immunosorbent assay (ELISA). Moreover, we measured the
120 antibody titer, and both outcomes (seropositivity and antibody titer) were tested to know the
121 association of different factors.

122 **Materials and Methods**

123 **Study design and setting**

124 From February to September 2021, we conducted a cross-sectional population-based study among
125 HCWs (e.g., doctors, nurses, hospital staff, ward boy, and cleaner), garment workers, and indoor
126 and outdoor patients (non-COVID-19) of six government and private hospitals each, and two
127 garment factories in CMA. All hospitals belonging to the study area were stratified according to
128 their affiliation status; government and private. From each stratum, six hospitals were randomly
129 selected. Sample size was calculated considering the following parameter: 0.65 proportion, 5%
130 margin of error, 95% confidence limit and design effect 2. Each organization's human resources
131 department provided a list of personnel. Following a simple random sampling technique, samples
132 were collected from a total of 748 respondents.

133 We interviewed participants to collect information after receiving written consent. Answering a
134 questionnaire and taking blood to test SARS CoV-2 antibodies were part of the study procedure.
135 Our study followed a World Health Organization protocol for population-level COVID-19
136 antibody testing [35]. The questionnaire included sociodemographic details and factors

137 hypothesized to be associated with seropositivity. Participants were included in the study based on
138 several inclusion criteria.

139 Inclusion criteria:

- 140 • **Asymptomatic:** Only an asymptomatic group was included to ensure the presence of
141 antibodies. Participants had no COVID-19 related clinical signs, e.g., fever, coughing, runny
142 nose, sore throat, dyspnea, shortness of breath, aches and pain at the time of sample collection
- 143 • **In case of having past confirmed COVID-19 status (by Rt PCR):**
 - 144 i. Participants who had already passed at least 28 days after a negative Rt-PCR test.
 - 145 ii. Participants who did not take a repeated test to ensure negativity had passed at least 42
146 days after the first COVID-19 test.

147 Besides, persons under 18 were excluded, as were those with an incomplete questionnaire.

148 **Baseline blood collection and processing**

149 Heparinized blood specimens (6mL) were collected and transported to the clinical pathology
150 laboratory (CPL) of Chattogram Veterinary and Animal Sciences University (CVASU) within
151 three hours of collection. The serum was separated to evaluate the IgG antibody and kept at -20 °C
152 until serological investigation.

153 **Serological test examination**

154 Antibody was determined by a commercial qualitative assay using COVID-19 IgG ELISA test
155 (Beijing Kewei Clinical Diagnostic Reagent Inc., China; Ref: 601340) as per the manufacturer's
156 instructions. The assay is an enzyme-linked immunoassay (ELISA) that detects IgG against the
157 SARS-CoV-2. An index (Absorbance/Cutt-off) of <1 was interpreted as negative, 0.9 to 1.1 as

158 borderline (retesting of these specimens in duplicates was done to confirm results), and ≥ 1 index
159 as positive. Per the manufacturer, the sensitivity and specificity of the assay for IgG are 93.8% and
160 97.3%, respectively. Positive and negative controls were included in all assay batches. Repeated
161 testing using the same specimen yielded the same interpretation.

162 The concentration of IgG antibodies was determined by SARS-CoV-2 S1-RBD IgG (DiaSino®
163 Laboratories Co., Ltd. Zhengzhou, China, Ref: DS207704), which is based on enzyme-linked
164 immunoassay for the quantitative detection of IgG antibodies. The assay's sensitivity and
165 specificity for IgG quantification, according to the manufacturer, are 98.41% and 98.02%,
166 respectively. Quantitative results were calculated as a ratio of the extinction of the control or tested
167 specimen over the extinction of the calibrator. Results were reported in standardized units for the
168 quantitative kits that included six calibrators to quantify the antibody concentration (i.e., DiaSino
169 units/mL). A value of <10 DU/mL was considered negative, and values >10 DU/mL were
170 positive.

171 **Data management**

172 The linearity of the quantitative variables was evaluated by categorizing them into four categories
173 using quartiles as cut-off values. Logistic regression analysis was conducted on the categorized
174 variables, and parameter estimates were observed for an increasing or decreasing trend. In case of
175 linear increase or decrease in the parameter estimates, linearity in the quantitative variable was
176 assumed and used without modification. In the case of nonlinearity, a quartile was used to
177 categorize it. However, some quantitative variables were categorized considering research interest.
178 For instance, the number of days between the first dose of vaccine and quantification of antibody
179 titer was categorized as 'after one month' and 'after two months' and between the second dose of
180 vaccine and quantification of antibody titer was categorized as 'after two months', 'after four

181 months' and 'after six months'. The number of days between the vaccination and the antibody titer
182 was achieved from the date of vaccination and sample collection. The prevalence estimates were
183 adjusted with the test kit performance (sensitivity and specificity), and the adjusted prevalence was
184 denoted as true prevalence.

185 **Data analysis**

186 In the study period, a total of 748 qualitative and quantitative test results were included in the
187 analysis. To evaluate the correlation and collinearity in the categorical and quantitative variables,
188 Cramer's V test, Spearman correlation coefficient, Chi-square test, t-test or ANOVA, where
189 appropriate, was used. Variables with a significant association or a Spearman correlation
190 coefficient above 0.4 were regarded as correlated. The effects of different potential explanatory
191 variables on the binary outcome - presence/absence of anti-SARS-CoV-2 antibody, was evaluated
192 using univariable and followed by multivariable logistic regression models. To select the final
193 multivariable model, all variables with a significant p-value in the univariable models were
194 included in a model and a manually conducted backward selection strategy was followed by
195 deleting one variable at a time with the highest P-value. Interactions between all explanatory
196 variables (2 ways) were evaluated in the final model. Effect of variables on the mean titer of the
197 antibody was assessed by t-test and one way ANOVA. P-values <0.05 were considered as
198 significant throughout the analysis. STATA-IC 13 (StataCorp, California, USA) and GraphPad
199 Prism 7.00 for Windows (GraphPad Software, La Jolla, California, USA) were used for statistical
200 analyses and visualization.

201 **Ethical approval and informed consent**

202 Institutional ethical approval was taken from the authorized committee of Chattogram Veterinary
 203 and Animal Sciences University (CVASU), Bangladesh [CVASU/Dir(R&E) EC/2020/212(1)].

204 **Results**

205 **Sero-prevalence of SARS-CoV-2 infection**

206 SARS-CoV-2 IgG antibodies were detected in 498 (66.99%) of 748 individuals (**Table 1**).

207 Prevalence of anti-SARS-CoV-2 antibody (IgG) in different donor types along with vaccination
 208 percentage is shown in **Figure 1**.

209

Table 1: Prevalence estimation in CMA						
Anti-SARS CoV-2 antibody	Total population	Unadjusted seroprevalence, % (95% CI)		Test performance adjusted seroprevalence % (95% CI)		Known positives (RT-qPCR positive) (%)
Present	498	66.58	(63.1-70.0)	66.99	(63.40-70.40)	91 (80.53)
Absent	250	33.42	(30.1-36.9)	32.60	(29.20-36.19)	22 (19.47)

210

211

212 **Figure 1:** Prevalence of anti-SARS-CoV-2 antibody (IgG) in different donor types along with
 213 vaccinated percent.

214

215 **Characteristics of study participants**

216 From February -September 2021, we enrolled 748 CMA service providers (362 HCWs, 205
 217 garments workers, 179 indoor/outdoor patients). Among them, 27.48% were garment workers, 150
 218 (20.11%) hospital staff, 145 (19.44%) doctors, 148 (19.84%) outdoor patients, 67 (8.98%) nurses,
 219 and 31 (4.16%) indoor patients. The majority (n=507; 67.96%) were males. In the total population,
 220 292 (39.14%) did not receive any COVID-19 vaccine, 223 (29.89%) received the first dose of
 221 vaccine, and 231 (30.97%) received both doses of the vaccine. The responses regarding contact
 222 with confirmed COVID-19 cases were: yes (342; 47.17%), no (307; 42.34%), and unknown (76;
 223 10.48%). One hundred and ninety-seven (32.35%) participants had pre-existing medical
 224 conditions (**Table 2**).

225

Table 2: Baseline characteristics of study participants				
Variables	Level	Total population	Known positives (RT-qPCR positive)	Asymptomatic
Donor type	Doctor	145 (19.44)	40 (35.40)	85 (16.13)
	Nurse	67 (8.98)	19 (16.81)	43 (8.16)
	Hospital staff	150 (20.11)	27 (23.89)	109 (20.68)
	Indoor patient	31 (4.16)	2 (1.77)	26 (4.93)

	Outdoor patient	148 (19.84)	21 (18.58)	109 (20.68)
	Garments worker	205 (27.48)	4 (3.54)	155 (29.41)
Gender	Male	507 (67.96)	73 (65.18)	362 (68.69)
	Female	239 (32.04)	39 (34.82)	165 (31.31)
Age (year)	19 to 29	201 (26.91)	15 (13.27)	149 (28.27)
	30 to 35	184 (24.63)	30 (26.55)	123 (23.34)
	36 to 44	180 (24.10)	34 (30.09)	123 (23.34)
	45 to 84	182 (24.36)	34 (30.09)	132 (25.05)
Vaccination	No	292 (39.14)	11 (9.82)	222 (42.13)
	Only 1 st dose	223 (29.89)	38 (33.93)	153 (29.03)
	Both doses	231 (30.97)	63 (56.25)	152 (28.84)
Days passed after 1 st dose of vaccine	14 to 30 days	45 (24.06)	8 (25.81)	30 (23.08; 16.1-31.3)
	31 to 60 days	142 (75.94)	23 (74.19)	100 (76.92)
Days passed after 2 nd dose vaccine	14 to 60 days	19 (8.26)	6 (9.38)	12 (8.00)
	61 to 120 days	86 (37.39)	20 (31.25)	60 (40.00)
	120 to 180 days	125 (54.35)	37 (59.38)	78 (52.00)
Days between PCR test and antibody test	21 to 60 days	-	17 (15.60)	-
	61 to 120 days	-	16 (14.68)	-
	121 to 180 days months	-	23 (21.10)	-
	>180 days	-	53 (48.62)	-

Contact with confirmed case	Yes	342 (47.17)	79 (71.17)	230 (45.19)
	No	307 (42.34)	17 (15.32)	232 (45.58)
	Don't know	76 (10.48)	15 (13.51)	47 (9.23)
Family member	1 to 3	186 (26.23)	31 (29.52)	130 (25.79)
	4 to 6	443 (62.48)	64 (60.95)	321 (63.69)
	≥7	80 (11.28)	10 (9.52)	53 (10.52)
Taking immunosuppressive drugs	Yes	15 (2.13)	7 (6.42)	8 (1.63)
	No	688 (97.87)	102 (93.58)	484 (98.37)
Comorbidities	Yes	197 (32.35)	38 (37.25)	291 (68.79)
	No	412 (67.65)	64 (62.75)	132 (31.29)

226

227 SARS-CoV-2 antibody titer

228 Indoor/outdoor patients had the highest mean titer of 197.18 DU/mL, followed by HCWs (163.30
 229 DU/mL) and garment workers (77.05 DU/mL) ($p < 0.001$). The level (mean) of IgG-spike
 230 antibodies in both dosage vaccine recipients was higher (255.46 DU/mL) than in those who
 231 received one (159.08 DU/mL) or no doses (53.71 DU/mL) of the vaccine ($p < 0.001$). When the
 232 participants had a contact with confirmed cases had a mean titer of 170.89 DU/mL, not known had
 233 a titer of 160.05 DU/mL, and in case of noncontact 116.45 DU/mL ($p < 0.001$). The mean titer of
 234 different age groups was statistically significant; nevertheless, we removed this variable from
 235 further analysis to minimize the bias due to vaccination strategy followed in Bangladesh (priority

236 given to aged); details in **Table 3**. The changes in mean titer of IgG antibody across different time
 237 intervals of intervention (one and both doses of vaccination) is illustrated in **Figure 2**.
 238

Table 3: Univariable analysis (ttest, one way ANOVA) to evaluate the mean difference of quantity of anti-SARS-CoV-2 antibody in serum samples

Variable	Level	Mean titer of IgG (DU/ml)	SD	P-value
Doner type	Health worker	163.30	153.54	<0.001
	Indoor/outdoor patient	197.18	147.04	
	Garments worker	77.05	115.63	
Gender	Female	140.09	151.36	0.31
	Male	151.83	148.38	
Age (year)	19 to 29	106.90	132.23	<0.001
	30 to 35	151.16	157.71	
	36 to 44	160.85	143.08	
	45 to 84	176.95	155.92	
Vaccination	No	53.71	91.16	<0.001
	Only 1st dose	159.08	161.05	
	Both doses	255.46	117.04	
Days passed after 1st dose of	31 to 60 days	131.39	152.08	0.10
	14 to 30 days	175.10	164.09	

vaccine				
Days passed after	120 to 180 days	147.09	119.29	0.02
2nd dose vaccine	61 to 120 days	255.82	106.00	
	14 to 60 days	324.42	128.42	
Asymptomatic	No	190.01	161.93	<0.001
	Yes	130.03	140.19	
Had COVID-19 confirmed status	No	191.69	142.70	0.005
	Yes	244.87	159.74	
Contact with confirmed case	No	116.45	135.21	<0.001
	Yes	170.89	154.19	
	Don't know	160.05	158.98	
Taking immunosuppressive drugs	No	143.02	150.09	0.32
	Yes	181.38	152.08	

239

240 **Figure 2:** Evaluation of time effects of vaccines mean difference of quantitative anti-SARS-CoV-2
 241 antibody (IgG) in serum samples.

242

243 Risk factor analysis

244 Univariable analysis (χ^2 test, logistic regression) to evaluate the association of different variables
 245 with the seroprevalence of anti-SARS-CoV-2 antibody

246 Indoor/outdoor patients amongst the different donor groups had a positivity rate of 81.37% (144
 247 of 179) compared to 68.99% (248 of 362) in the HCWs and 50.56% in the garments workers (104

248 of 205); the difference was statistically significant ($p < 0.001$). Both doses of vaccine receivers
 249 showed significantly ($p < 0.001$) higher seropositivity than one dose or no vaccine receivers.
 250 Similarly, contact with confirmed COVID-19 cases showed a higher odd of being seropositive as
 251 compared to noncontact ($p = 0.01$) [OR= 1.59] (Table 4).
 252

Table 4: Univariable analysis (χ^2 test, logistic regression) to evaluate the association of different variables with seroprevalence of anti-SARS-CoV-2 antibody					
Variable	Level (n)	Presence of IgG	TP (95% CI of TP) **	OR	P-value
Donor type	Health worker (362)	248	68.99 (63.8-73.7)	Ref.	<0.001
	Indoor/outdoor patient (179)	144	81.37 (74.7-86.7)	1.8	
	Garments worker (205)	104	50.56 (43.5-57.5)	0.47	
Gender	Female (239)	151	63.47 (56.9-69.5)	Ref.	0.15
	Male (507)	347	68.92 (64.6-72.9)	1.26	
Age (year)	19 to 29 (201)	114	56.76 (49.5-63.6)	Ref.	0.002

	30 to 35 (184)	119	65.01 (57.6-71.8)	1.39	
	36 to 44 (180)	132	73.99 (66.8-80.1)	2.09	
	45 to 84 (182)	133	73.73 (66.6-79.8)	2.07	
Vaccination	No (292)	131	44.47 (38.6-50.4)	Ref.	<0.001
	Only 1st dose (223)	137	61.66 (54.8-68.0)	1.95	
	Both doses (231)	229	100 (98.4-100.0)	140.72	
Days passed after 1st dose of vaccine	31 to 60 days (142)	79	55.64 (47.1-63.8)	Ref.	0.29
	14 to 30 days (45)	29	64.78 (49.6-77.5)	1.44	
Days passed after 2nd dose vaccine	120 to 180 days (125)	123	99.9 (95.7- 100)	-	-
	61 to 120 days (86)	86	100 (97.2-100)	-	
	14 to 60 days (19)	19	100 (84.2-100)	-	

Asymptomatic	No (220)	160	73.36 (66.9-79.03)	Ref.	0.13
	Yes (528)	355	67.66 (63.4-71.68)	0.76	
Had COVID-19 confirmed status	No (144)	119	83.65 (76.3-89.1)	Ref.	0.66
	Yes (113)	91	81.46 (72.9-87.9)	0.86	
Contact with confirmed case	No (307)	187	61.11 (55.3-66.6)	Ref.	0.01
	Yes (342)	244	71.93 (66.7-76.6)	1.59	
	Don't know (76)	49	64.81 (53.1-75.0)	1.16	
Taking immunosuppressive drugs	No (688)	447	65.32 (61.5-68.9)	Ref.	0.20
	Yes (15)	12	80.91 (54.7-94.3)	2.15	

253 **TP=True prevalence

254 Multivariable analysis (logistic regression) to determine the potential factors associated with

255 SARS-CoV-2 antibody-positive status in the study area

256 The multivariable logistic regression model identified two potential factors that might be
 257 influencing the seropositivity of SARS-CoV-2 antibodies in the studied population. The chance of
 258 being seropositive was 2.22 times higher in indoor/outdoor patients ($p= 0.002$) and 1.69 times for
 259 garments workers than HCWs ($p= 0.01$). Further, both doses of vaccine receivers had a higher
 260 chance of being positive (OR=174.02) than one dose (OR=2.34) or none dose receivers, and the
 261 difference was statistically significant ($p< 0.001$) (**Table 5**).

262

Table 5: Output from the final multivariable logistic regression model showing the adjusted effect of potential factors on the seroprevalence of anti-SARS-CoV-2 antibody				
Variable	Level	OR	95% CI	P-value
Doner type	Health worker	Ref.		
	Indoor/outdoor patient	2.22	1.33-3.68	0.002
	Garments worker	1.69	1.09-2.62	0.01
Vaccination	No	Ref.		
	Only 1st dose	2.34	1.56-3.50	<0.001
	Both doses	174.02	41.46-730.40	<0.001

263

264 **Discussion**

265 The overall adjusted seroprevalence estimate of SARS-CoV-2 antibodies was 66.99% (95% CI:
 266 63.40%-70.4%) in CMA in this research which is slightly higher than a previous finding (64.1%)
 267 using an immunoassay test to detect antibodies in the Sitakunda sub-district (Chattogram district)

268 of Bangladesh from March to June 2021 [36]. Another research conducted by icddr'b between
269 October 2020 and February 2021 found a lower (55%) estimate in Chattogram than ours. During
270 the same study period, however, the adjusted seroprevalence in Dhaka, the capital of Bangladesh,
271 was 71% [37]. Thus, based on several investigations, it can be assumed that seropositivity in
272 Chattogram has been progressively increasing over time. The prevalence might have increased due
273 to either high infection levels or a positive response to the national immunization campaign in its
274 early phases [38]. According to the findings, 68.99% HCWs and 81.37% indoor/outdoor patients
275 were seropositive. Indoor and outdoor patients were more likely than health professionals to be
276 seropositive, possibly due to the combined effect of lack of awareness and knowledge about
277 COVID-19 among some of them and effect of vaccination as they might be were composed of a
278 mixed population of lower to upper socio-economic status and with different educational levels.
279 Tripathi et al., 2020 reported that HCWs were more educated of COVID-19 symptoms, incubation
280 time, problems in high-risk patients, and had greater access to therapy than other residents (non
281 HCWs) [39]. In Navi Mumbai in May 2021, serosurveillance of anti-SARS-Cov-2 antibodies
282 among essential workers revealed that police personnel had a 72% seropositivity rate, whereas
283 HCWs had a 48% positivity rate [40]. Moreover, we observed that, among the garment workers,
284 just under 20% received vaccines and just above 50% were seropositive, which might have majorly
285 been achieved from natural infections (**Figure 1**). It might indicate their lack of awareness about
286 disease transmission and vaccination.

287 We found that the IgG antibody was produced in 61.66% of the participants who received the first
288 dose of COVID-19 vaccination. This number increased to 100% among individuals who received
289 a second dose. In a study by Bayram et al., 2021, HCWs' seropositivity rates after the first and
290 second doses of CoronaVac vaccination were found to be 77.8% and 99.6%, respectively [41].

291 Subsequently, when we quantified the antibody titer, we observed it higher in those who received
292 the second dose than in those who received just the first. Detection of highly avid anti-S1/-RBD
293 IgG, independent of the causal mechanism, is seen as a very positive indication and indicator of
294 enhanced humoral immunity [42].

295 Human coronavirus infection may not always result in long-lasting antibody responses, with
296 antibody titers dropping over time [43]. The waning of antibody responses is an essential element
297 to consider while developing a coronavirus vaccine [44]. Our study showed that by the second
298 month following the initial dose, the mean IgG titer in the body had dropped by nearly 25%.
299 However, the antibody's propensity to deteriorate with time was noteworthy. This study revealed
300 that the available mean antibody titers that remained after two months of receiving the second dose
301 had dropped by roughly 21% by the fourth month, and within the sixth month the mean antibody
302 titer was 147.09 DU/mL. So, it can be assumed that the body still retained considerable antibodies
303 against COVID-19 six months after receiving the second dose vaccine, though the threshold level
304 to prevent the virus is not known.

305 The underreporting of SARS-CoV-2 infection cases makes it difficult to assess the actual infection
306 burden. Limited testing, flaws in the reporting infrastructure, and a substantial proportion of
307 asymptomatic infections contribute to the underreporting [45]. Asymptomatic carriers spread
308 COVID-19, but the clinical characteristics, viral dynamics, and antibody responses of these
309 individuals are unknown [46]. According to our findings, 67.66% of the asymptomatic population
310 was seropositive where only 29.03 % of asymptomatic individuals received the first dose of
311 COVID-19 vaccine, and 28.84 % received the second dose too. According to various population-
312 based studies, a considerable majority of seropositive people were asymptomatic or had no known
313 encounter with a COVID-19 patient [47-49]. Meanwhile, the observation that asymptomatic

314 people had lower mean IgG levels than symptomatic people back up previous findings that
315 asymptomatic carriers have a lesser humoral immune response to COVID-19 infection [47,50].
316 The study also revealed that people aged above 35 had a greater seroprevalence. Higher
317 seroprevalence among adults could be associated with increased vaccination exposure. On January
318 26 of this year, the government began accepting registrations for the COVID-19 vaccine for
319 persons aged 55 and up in the country [51]. In the second phase, the age limit was dropped to 40
320 years or more, and vaccination of youngsters aged 12-17 has recently begun in the country [52].

321 The latest and more deadly SARS-CoV-2 viral strains, as well as the possibility of losing immunity
322 with time after vaccination, have prompted health professionals to consider the need for boosters.
323 Research on threshold titers giving protection and time intervals of declining immunity post-
324 immunization for low-middle-income nations like Bangladesh are essential before launching
325 further booster doses. An important application of serological tests is to determine the antibody
326 responses generated upon SARS-CoV-2 infection and vaccination [53]. The continuation of this
327 study on those who received the second dose more than six months ago will provide an appropriate
328 booster interval, risk population category, and overview of herd immunity. According to a recent
329 study conducted in the greater Chattogram division it is evident that administering the first dose
330 (Oxford-AstraZeneca) vaccine significantly reduces health risk during the COVID-19 infection
331 phase [54]. So, it is evident that similar research is clamoring for justifications for booster
332 administration. Additionally, more research is required to assess the efficacy of booster doses.
333 Government and healthcare professionals must adopt COVID-19 vaccine booster dose utilization
334 guidelines that consider the risks of fading immunity, new virus strains, and prioritizing vulnerable
335 groups.

336 Our study has several limitations, such as the fact that we only collected samples from hospitals
337 and the garment industry, but the results would be more representative of the community if we
338 included other groups. We could not compare immunological responses produced by different
339 COVID-19 vaccine brands at the same post-vaccination interval since distinct COVID-19 vaccines
340 were licensed and supplied to CMA at different times. We did not reveal the type and name of
341 COVID-19 vaccines, whereas a sufficient fraction was not covered under the vaccination program,
342 and we were concerned about an infodemic.

343

344 **Acknowledgment**

345 The authors acknowledge Bangladesh Institute of Tropical and Infectious Diseases (BITID),
346 Chattogram General Hospital, Chittagong Medical University, Medical Center (Pvt.), Imperial
347 Hospital Limited, Chattogram Asian Apparels Limited, Clifton Garments Limited, Bangladesh
348 Garment Manufacturers and Exporters Association (BGMEA) Chattogram, and BGMEA Hospital
349 and Diagnostic Center for providing samples and administrative support. The laboratory facilities
350 were supported by the Dept. of Pathology and Parasitology, CVASU. The authors sincerely
351 acknowledge the One Health Institute, CVASU for logistic support.

352

353 **Conflict of interest**

354 The authors have no potential conflict of interest.

355

356 **Authors Contribution**

357 **JA:** Conceptualization, methodology, project proposal writing, administration, data curation,
358 writing-original draft, review and editing. **MSI:** Conceptualization, methodology, project

359 administration, laboratory tasks, data visualization, writing-original draft, review and editing.
360 **MTUQ:** Sample collection, data curation. **AD:** Sample collection, data curation. **FMYH:**
361 Laboratory tasks. **MSI:** Sample collection, data curation. **TR:** Sample collection, data curation.
362 **SD:** Data curation, writing review and editing. **MAHC:** Conceptualization, investigation,
363 methodology, supervision, and reviewing-final manuscript. **GBD:** Project investigation, fund
364 acquisition, and reviewing-final manuscript. **SC:** Conceptualization, investigation, methodology,
365 supervision, data- validation, analysis, visualization, writing-original draft, and reviewing-final
366 manuscript.

367

368 **Funding Information**

369 The study was funded by the Director of Research & Extension, CVASU.

370

371 **References**

372 1. Rana EA, Chowdhury NS, Islam MS, Ara J, Nasrin SS, Dutta P, Bristi SZ, Nizami TA,
373 Chakraborty P, Siddiki AZ. Molecular detection and prevalence of SARS-CoV-2 during the
374 early outbreak in southern Bangladesh. *International Journal of One Health*. 2020;6(2):153-9.

375 2. Dhaka Tribune, First Coronavirus Case Confirmed in Chittagong, 6 Buildings in Lockdown.

376 2020 April 3. [Internet]. Available from:

377 <https://archive.dhakatribune.com/bangladesh/nation/2020/04/03/covid-19-first-case-confirmed->

378 [in-chittagong](https://archive.dhakatribune.com/bangladesh/nation/2020/04/03/covid-19-first-case-confirmed-in-chittagong)

- 379 3. Dhaka Tribune, Another Corona Virus Patient Dies in Chittagong. 2020 April 13. [Internet].
380 Available from: <https://www.dhakatribune.com/health/coronavirus/2020/04/13/another->
381 [coronavirus-patient-dies-in-chittagong](https://www.dhakatribune.com/health/coronavirus/2020/04/13/another-coronavirus-patient-dies-in-chittagong)
- 382 4. Goenka MK, Afzalpurkar S, Goenka U, Das SS, Mukherjee M, Jajodia S, Shah BB, Patil
383 VU, Rodge G, Khan U, Bandyopadhyay S. Seroprevalence of COVID-19 amongst health care
384 workers in a tertiary care hospital of a metropolitan city from India.
- 385 5. Vernet R, Charrier E, Grogg J, Mach N. A Quantitative ELISA Protocol for Detection of
386 Specific Human IgG against the SARS-CoV-2 Spike Protein. *Vaccines*. 2021 Jul;9(7):770.
- 387 6. Bryant JE, Azman AS, Ferrari MJ, Arnold BF, Boni MF, Boum Y, Hayford K, Luquero FJ,
388 Mina MJ, Rodriguez-Barraquer I, Wu JT. Serology for SARS-CoV-2: Apprehensions,
389 opportunities, and the path forward. *Science immunology*. 2020 May 19;5(47):eabc6347.
- 390 7. Shakiba M, Nazemipour M, Salari A, Mehrabian F, Nazari SS, Rezvani SM, Ghasempour Z,
391 Heidarzadeh A, Mansournia MA. Seroprevalence of SARS-CoV-2 in Guilan Province, Iran,
392 April 2020. *Emerging infectious diseases*. 2021 Feb;27(2):636.
- 393 8. Bendavid E, Mulaney B, Sood N, Shah S, Bromley-Dulfano R, Lai C, Weissberg Z,
394 Saavedra-Walker R, Tedrow J, Bogan A, Kupiec T. Covid-19 antibody seroprevalence in santa
395 clara county, california. *International journal of epidemiology*. 2021 Apr;50(2):410-9.
- 396 9. Gomes LR, Durans AM, Napoleão-Pêgo P, Waterman JA, Freitas MS, De Sá NB, Pereira
397 LV, Furtado JS, Aquino RG, Machado MC, Fintelman-Rodrigues N. Multiepitope Proteins for

- 398 the Differential Detection of IgG Antibodies against RBD of the Spike Protein and Non-RBD
399 Regions of SARS-CoV-2. *Vaccines*. 2021 Sep;9(9):986.
- 400 10. Freeman B, Lester S, Mills L, Rasheed MA, Moye S, Abiona O, Hutchinson GB, Morales-
401 Betoulle M, Krapinunaya I, Gibbons A, Chiang CF. Validation of a SARS-CoV-2 spike protein
402 ELISA for use in contact investigations and serosurveillance. *Biorxiv*. 2020 Jan 1.
- 403 11. Brown TS, Walensky RP. Serosurveillance and the COVID-19 epidemic in the US:
404 undetected, uncertain, and out of control. *Jama*. 2020 Aug 25;324(8):749-51.
- 405 12. Hossain M, Das SC, Raza MT, Ahmed IU, Eva IJ, Karim T, Chakraborty P, Gupta SD.
406 Immediate and post-COVID complications of symptomatic and asymptomatic COVID-19
407 patients in Bangladesh: a cross-sectional retrospective study. *Asian Journal of Medical and*
408 *Biological Research*. 2021 Jun 30;7(2):191-201.
- 409 13. Thomas SN, Altawallbeh G, Zaun CP, Pape KA, Peters JM, Titcombe PJ, Dileepan T, Rapp
410 MJ, Bold TD, Schacker TW, Arbefeville S. Initial determination of COVID-19 seroprevalence
411 among outpatients and healthcare workers in Minnesota using a novel SARS-CoV-2 total
412 antibody ELISA. *Clinical Biochemistry*. 2021 Apr 1;90:15-22.
- 413 14. Lerner AM, Eisinger RW, Lowy DR, Petersen LR, Humes R, Hepburn M, Cassetti MC. The
414 COVID-19 serology studies workshop: recommendations and challenges. *Immunity*. 2020 Jul
415 14;53(1):1-5.

- 416 15. Wang H, Wiredja D, Yang L, Bulterys PL, Costales C, Röltgen K, Manalac J, Yee J,
417 Zehnder J, Shi RZ, Boyd SD. Case-Control Study of Individuals with Discrepant Nucleocapsid
418 and Spike Protein SARS-CoV-2 IgG Results. *Clinical Chemistry*. 2021 Mar 15.
- 419 16. Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E,
420 Arnthorsson AO, Helgason D, Bjarnadottir K, Ingvarsson RF, Thorsteinsdottir B. Humoral
421 immune response to SARS-CoV-2 in Iceland. *New England Journal of Medicine*. 2020 Oct
422 29;383(18):1724-34.
- 423 17. Aljazeera, Coronavirus Pandemic, Bangladesh Starts COVID Vaccination Drive. 2021 Jan
424 28. [Internet]. Available from: [https://www.aljazeera.com/news/2021/1/28/bangladesh-starts-](https://www.aljazeera.com/news/2021/1/28/bangladesh-starts-covid-vaccination-drive)
425 [covid-vaccination-drive](https://www.aljazeera.com/news/2021/1/28/bangladesh-starts-covid-vaccination-drive)
426
- 427 18. Anadolu Agency, World, Asia-Pacific, Latest on CoronavirusOutbreak, Bangladesh Starts
428 Nationwide COVID Vaccination Drive. 2021 Feb 7. [Internet]. Available from:
429 [https://www.aa.com.tr/en/asia-pacific/bangladesh-starts-nationwide-covid-vaccination-](https://www.aa.com.tr/en/asia-pacific/bangladesh-starts-nationwide-covid-vaccination-drive/2136643)
430 [drive/2136643](https://www.aa.com.tr/en/asia-pacific/bangladesh-starts-nationwide-covid-vaccination-drive/2136643)
- 431 19. COVID-19 Vaccination Dashboard for Bangladesh, Health Emergency Control Center,
432 DHIS2, Surokkha App, **2022**. [Internet]. Available from:
433 <http://103.247.238.92/webportal/pages/covid19-vaccination-update.php>
- 434 20. Dhaka Tribune, Bangladesh Begins Booster Vaccination. 2021 Nov 28. [Internet]. Available
435 from: [https://newsarchive.app/a/dhakatribune/2021/11/28/Bangladesh-begins-booster-](https://newsarchive.app/a/dhakatribune/2021/11/28/Bangladesh-begins-booster-vaccination)
436 [vaccination](https://newsarchive.app/a/dhakatribune/2021/11/28/Bangladesh-begins-booster-vaccination)

- 437 21. Mahmud S, Mohsin M, Khan IA, Mian AU, Zaman MA. Knowledge, beliefs, attitudes and
438 perceived risk about COVID-19 vaccine and determinants of COVID-19 vaccine acceptance in
439 Bangladesh. *PloS one*. 2021 Sep 9;16(9): e0257096.
- 440 22. Bandyopadhyay S, Baticulon RE, Kadhum M, Alser M, Ojuka DK, Badereddin Y, Kamath
441 A, Parepalli SA, Brown G, Iharchane S, Gandino S. Infection and mortality of healthcare
442 workers worldwide from COVID-19: a systematic review. *BMJ global health*. 2020 Dec
443 1;5(12):e003097.
- 444 23. Bangladesh Medical Association. District wise total Number of Affected Doctor, Nurse &
445 Staff (COVID 19+) From 08/03/2020 till today on 28/09/2021. [Internet]. Available from:
446 <https://bma.org.bd/covid-19/Total%20Affected%20Doctor,%20Nurse%20&%20Staff.pdf>
- 447 24. Chen Q, Liang M, Li Y, Guo J, Fei D, Wang L, He LI, Sheng C, Cai Y, Li X, Wang J.
448 Mental health care for medical staff in China during the COVID-19 outbreak. *The Lancet*
449 *Psychiatry*. 2020 Apr 1;7(4): e15-6.
- 450 25. Mhango M, Dzobo M, Chitungo I, Dzinamarira T. COVID-19 risk factors among health
451 workers: a rapid review. *Safety and health at work*. 2020 Sep 1;11(3):262-5.
- 452 26. Iversen K, Bundgaard H, Hasselbalch RB, Kristensen JH, Nielsen PB, Pries-Heje M,
453 Knudsen AD, Christensen CE, Fogh K, Norsk JB, Andersen O. Risk of COVID-19 in health-care
454 workers in Denmark: an observational cohort study. *The Lancet Infectious Diseases*. 2020 Dec
455 1;20(12):1401-8.

- 456 27. Ehrlich H, McKenney M, Elkbuli A. Protecting our healthcare workers during the COVID-
457 19 pandemic. *The American journal of emergency medicine*. 2020 Jul 1;38(7):1527-8.
- 458 28. Shaw A, Flott K, Fontana G, Durkin M, Darzi A. No patient safety without health worker
459 safety. *The Lancet*. 2020 Nov 14;396(10262):1541-3.
- 460 29. Kontoangelos K, Economou M, Papageorgiou C. Mental health effects of COVID-19
461 pandemia: a review of clinical and psychological traits. *Psychiatry investigation*. 2020
462 Jun;17(6):491.
- 463 30. Khan AN, Ullah MR. Export scenario between Bangladesh and China: Opportunities of
464 Bangladesh in RMG Sector. *Eur Sci J*. 2017;13(28):299-320.
- 465 31. Hosen MS, Nafiujjaman M, Biswas FN. Garment employees are at higher risk than any other
466 workers in COVID-19 pandemic in Bangladesh. *Caspian Journal of Health Research*. 2020 Jan
467 10;5(1):1-2.
- 468 32. Dyal JW. COVID-19 among workers in meat and poultry processing facilities—19 states,
469 April 2020. *MMWR. Morbidity and mortality weekly report*. 2020;69.
- 470 33. Marinaccio A, Guerra R, Iavicoli S. Work a key determinant in COVID-19 risk. *The Lancet*
471 *Global Health*. 2020 Nov 1;8(11): e1368.
- 472 34. Islam MS, Hasib FY, Nath C, Ara J, Nu MS, Fazal MA, Chowdhury S. Coronavirus disease
473 2019 and its potential animal reservoirs: A review. *Health*. 2021 Jul 1;7(2):171-81.

- 474 35. World Health Organization, Population-Based Age-Stratified Seroepidemiological
475 Investigation Protocol for Coronavirus 2019 (COVID-19) Infection. 2020 May. [Internet].
476 Available from: [https://www.who.int/publications/i/item/WHO-2019-nCoV-Seroepidemiology-](https://www.who.int/publications/i/item/WHO-2019-nCoV-Seroepidemiology-2020.2)
477 2020.2
- 478 36. Bhuiyan TR, Hulse JD, Hegde S, Akhtar M, Islam T, Khan ZH, Khan II, Rashid M, Rashid
479 R, Shirin T, Gurley ES. SARS-CoV-2 seroprevalence in Chattogram, Bangladesh before a
480 National Lockdown, March-April 2021. medRxiv. 2021 Jan 1.
- 481 37. icddr,b, news, Higher COVID-19 Seropositivity Observed Among Residents in Dhaka and
482 Chattogram. 2021 June 22. [Internet]. Available from: [https://www.icddr.org/news-and-](https://www.icddr.org/news-and-events/news?id=878)
483 [events/news?id=878](https://www.icddr.org/news-and-events/news?id=878)
- 484 38. Ward H, Cooke G, Whitaker M, Redd R, Eales O, Brown JC, Collet K, Cooper E, Daunt A,
485 Jones K, Moshe M. REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies
486 demonstrate impact of the second wave and of vaccine roll-out in England. MedRxiv. 2021 Jan
487 1.
- 488 39. Tripathi R, Alqahtani SS, Albarraq AA, Meraya AM, Tripathi P, Banji D, Alshahrani S,
489 Ahsan W, Alnakhli FM. Awareness and preparedness of COVID-19 outbreak among healthcare
490 workers and other residents of South-West Saudi Arabia: a cross-sectional survey. *Frontiers in*
491 *Public Health*. 2020 Aug 18;8:482.
- 492 40. Maheshwari U, Sahai J, Hebbar V. Serosurveillance of Anti SARS-Cov-2 Antibodies among
493 Essential Workers in Navi Mumbai—A Single Centre Study. *International Journal of Health*
494 *Sciences and Research*. 2021;11(7):99-104.

- 495 41. Bayram A, Demirbakan H, Karadeniz PG, Erdoğan M, Koçer I. Quantitation of antibodies
496 against SARS-CoV-2 spike protein after two doses of CoronaVac in health care workers. *Journal*
497 *of medical virology*. 2021 May 21.
- 498 42. Neumann F, Rose R, Römpke J, Grobe O, Lorentz T, Fickenscher H, Krumbholz A.
499 Development of SARS-CoV-2 specific IgG and virus-neutralizing antibodies after infection with
500 variants of concern or vaccination. *Vaccines*. 2021 Jul;9(7):700.
- 501 43. Callow KA, Parry HF, Sergeant M, Tyrrell DA. The time course of the immune response to
502 experimental coronavirus infection of man. *Epidemiology & Infection*. 1990 Oct;105(2):435-46.
- 503 44. Amanat F, Krammer F. SARS-CoV-2 vaccines: status report. *Immunity*. 2020 Apr
504 14;52(4):583-9.
- 505 45. Bhattacharyya R, Kundu R, Bhaduri R, Ray D, Beesley LJ, Salvatore M, Mukherjee B.
506 Incorporating false negative tests in epidemiological models for SARS-CoV-2 transmission and
507 reconciling with seroprevalence estimates. *Scientific reports*. 2021 May 7;11(1):1-4.
- 508 46. Xiao T, Wang Y, Yuan J, Ye H, Wei L, Liao X, Wang H, Qian S, Wang Z, Liu L, Zhang Z.
509 Early viral clearance and antibody kinetics of COVID-19 among asymptomatic carriers.
510 *Frontiers in Medicine*. 2021;8.
- 511 47. Alkurt G, Murt A, Aydin Z, Tatli O, Agaoglu NB, Irvem A, Aydin M, Karaali R, Gunes M,
512 Yesilyurt B, Turkez H. Seroprevalence of coronavirus disease 2019 (COVID-19) among health
513 care workers from three pandemic hospitals of Turkey. *PloS one*. 2021 Mar 3;16(3): e0247865.

- 514 48. Mukhtar A, Alfshawy M, Alkhatib E, Hosny M, Ollaek M, Elsayed A, Salem MR, Ghaith
515 D. Asymptomatic SARS-CoV-2 infection among healthcare workers in a non-COVID-19
516 teaching university hospital. *Journal of Public Health Research*. 2021 Jun 24;10(3).
- 517 49. Selvaraju S, Kumar MS, Thangaraj JW, Bhatnagar T, Saravanakumar V, Kumar CP, Sekar
518 K, Ilayaperumal E, Sabarinathan R, Jagadeesan M, Hemalatha MS. Population-based serosurvey
519 for severe acute respiratory syndrome coronavirus 2 transmission, Chennai, India. *Emerging*
520 *Infectious Diseases*. 2021 Feb;27(2):586.
- 521 50. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, Hu JL, Xu W, Zhang Y, Lv FJ, Su K.
522 Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. *Nature*
523 *medicine*. 2020 Aug;26(8):1200-4.
- 524 51. Dhaka Tribune, Bangladesh Lowers Covid-19 Vaccine Age Limit to 18 Years. 2021 Oct 20.
525 [Internet]. Available from: [https://www.dhakatribune.com/bangladesh/2021/10/20/bangladesh-](https://www.dhakatribune.com/bangladesh/2021/10/20/bangladesh-lowers-covid-19-vaccine-age-limit-to-18-years)
526 [lowers-covid-19-vaccine-age-limit-to-18-years](https://www.dhakatribune.com/bangladesh/2021/10/20/bangladesh-lowers-covid-19-vaccine-age-limit-to-18-years)
- 527 52. Dhaka Tribune, COVID Vaccination Campaign for School Students. 2021 Nov 1. [Internet].
528 Available from: [https://www.dhakatribune.com/bangladesh/2021/11/01/covid-vaccination-](https://www.dhakatribune.com/bangladesh/2021/11/01/covid-vaccination-campaign-for-school-students-kicks-off)
529 [campaign-for-school-students-kicks-off](https://www.dhakatribune.com/bangladesh/2021/11/01/covid-vaccination-campaign-for-school-students-kicks-off)
- 530 53. Krammer F, Simon V. Serology assays to manage COVID-19. *Science*. 2020 Jun
531 5;368(6495):1060-1.

- 532 54. Rana EA, Dutta P, Islam MS, Nizami TA, Das T, Chowdhury S, Das GB. Severity
533 assessment of single dose Oxford–AstraZeneca vaccinated individuals infected with SARS CoV-
534 2 in the Southeast Bangladesh. medRxiv. 2021 Jan 1.




Figure 1




Figure 2